Brown R H, Stewart R H, Lynch M G, Crandall A S, Mandell A I, Wilensky J T, Schwartz A L, Gaasterland D E, DeFaller J M, Higginbotham E J
Department of Ophthalmology, University of Texas Health Science Center, Dallas 75235-9057.
Ophthalmology. 1988 Mar;95(3):378-84. doi: 10.1016/s0161-6420(88)33185-4.
The effect of an alpha adrenergic agonist, ALO 2145 (para-amino-clonidine [PAC]), was examined in a double-masked, multicenter study on the postoperative intraocular pressure (IOP) elevation after laser surgery in 165 patients (83 trabeculoplasty, 36 iridotomy, and 46 capsulotomy). One drop of 1.0% ALO 2145 or vehicle was instilled 1 hour before and immediately after laser surgery. The mean IOP increase in the ALO 2145-treated group was lower (P less than 0.05) than in the placebo group at each of the first three postoperative hours. Overall, 18% of placebo-treated eyes experienced IOP increases greater than or equal to 10 mmHg as compared with 4% of ALO 2145-treated eyes (P less than 0.003). Ocular and systemic side effects were minimal and did not differ between the treatment groups. ALO 2145 safely and effectively reduced the incidence and magnitude of potentially harmful IOP elevations after anterior segment laser surgery.
在一项双盲、多中心研究中，对165例患者（83例行小梁成形术、36例行虹膜切开术、46例行晶状体囊切开术）进行了α肾上腺素能激动剂ALO 2145（对氨基可乐定[PAC]）对激光手术后眼内压（IOP）升高影响的研究。在激光手术前1小时和手术后立即滴入一滴1.0%的ALO 2145或赋形剂。在术后的前三个小时中，接受ALO 2145治疗的组的平均IOP升高幅度低于安慰剂组（P<0.05）。总体而言，安慰剂治疗组中有18%的眼睛IOP升高大于或等于10 mmHg，而ALO 2145治疗组为4%（P<0.003）。眼部和全身副作用极小，且治疗组之间无差异。ALO 2145安全有效地降低了眼前节激光手术后潜在有害的IOP升高的发生率和幅度。
